end-stage kidney disease Articles
-
Will Metformin Be Replaced By SGLT-2 Inhibitors
Metformin is a classic first-line hypoglycemic agent for patients with type 2 diabetes, and is an essential drug in combination regimenes. However, as the evidence is updated, the idea of drug selection for first-line treatment is changing. GLP-1 agonists and SGLT-2 inhibitors in combination with or without metformin (as required for glycemic management) have also been recommended by multiple ...
-
Artio’s Amplifi System Treatment Before AVF Creation Studied in FIH Procedures
October 6, 2021—Surendra Shenoy, MD, presented findings from a first-in-human (FIH) evaluation of the Amplifi vein dilation system (Artio Medical, Inc.), which is a small, wearable blood pump device that dilates arm veins before arteriovenous fistula (AVF) creation. Amplifi is designed to improve AVF eligibility, reduce maturation failure, reduce time to maturation, and prolong primary ...
-
LimFlow Percutaneous Deep Venous Arterialization
What interested you in LimFlow, and how did you get involved in the PROMISE I trial? Dr. Clair: Practicing vascular surgery, where a number of patients are evaluated for chronic limb-threatening ischemia (CLTI), you are guaranteed to have patients who are not candidates for percutaneous or surgical revascularization. These patients often have arterial systems open or identifiable to the ankle, ...
-
Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage
Keywords Vascular access · Hemodialysis · Healthcare costs · Health economics · Arteriovenous fistula · Arteriovenous graft Abstract Introduction: Hemodialysis (HD) in end-stage renal disease (ESRD) patients requires vascular access (VA) through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter. While AVF or ...
-
Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection
Background: Synthetic expanded polytetrafluorethylene (ePTFE) grafts are routinely used for vascular repair and reconstruction but prone to sustained bacterial infections. Investigational bioengineered human acellular vessels (HAVs) have shown clinical success and may confer lower susceptibility to infection. Here we directly compared the susceptibility of ePTFE grafts and HAV to bacterial ...
-
Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Metaanalysis of Efficacy and Safety Outcomes
Background: Arteriovenous fistulae are the currently recommended gold standard vascular access modality for haemodialysis because of their prolonged patency, improved durability, and low risk of infection for those that mature. However, notable disadvantages are observed in terms of protracted maturation time, associated high rates of catheter use, and substantial abandonment rates. The aim of ...
-
Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure
Abstract Acute decompensated heart failure remains the most common cause of hospitalization in older adults, and studies of pharmacological therapies have yielded limited progress in improving outcomes for these patients. This has prompted the development of novel device–based interventions, classified mechanistically based on the way in which they intend to improve central hemodynamics, ...
-
Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access
Objective: Patients with end stage renal failure who require haemodialysis suffer morbidity and mortality due to vascular access. Bioengineered human acellular vessels (HAVs) may provide a haemodialysis access option with fewer complications than other grafts. In a prospective phase II trial from 2012 to 2014 (NCT01744418), HAVs were implanted into 40 haemodialysis patients at three sites in ...
-
An Early Study on the Mechanisms that Allow Tissue-Engineered Vascular Grafts to Resist Intimal Hyperplasia
Abstract : Intimal hyperplasia is one of the prominent failure mechanisms for arteriovenous fistulas and arteriovenous access grafts. Human tissue-engineered vascular grafts (TEVGs) were implanted as arteriovenous grafts in a novel baboon model. Ultrasound was used to monitor flow rates and vascular diameters throughout the study. Intimal hyperplasia in the outflow vein of TEVGs was assessed at ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you